Alcedis GmbH   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Giessen Germany (1992)

Organization Overview

First Clinical Trial
2015
NCT02308553
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Alcedis GmbH

Active Ingredients

Drugs in Phase 3 Trials (2)

losartan (cozaar) (1 trial)

prednisolone (hydeltra) (1 trial)

Drugs in Phase 2 Trials (5)

2x-121 (1 trial)

gemcitabine (gemzar) (1 trial)

nintedanib (ofev) (1 trial)

paclitaxel (taxol) (2 trials)

sco-101 (1 trial)

Drugs in Phase 1 Trials (1)

dapagliflozin (farxiga) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 1 (Phase 1)

Melanoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 8